Stay updated with breaking news from Nasdaq vktx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average […] ....
Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) gapped up before the market opened on Tuesday after Oppenheimer raised their price target on the stock from $30.00 to $35.00. The stock had previously closed at $21.33, but opened at $21.86. Viking Therapeutics shares last traded at $21.48, with a volume of 510,823 shares. Several other equities […] ....
Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) Director Lawson Macartney sold 16,000 shares of the business’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $22.00, for a total transaction of $352,000.00. Following the sale, the director now owns 47,965 shares of the company’s stock, valued at […] ....
Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) shares gapped up before the market opened on Tuesday after Oppenheimer raised their price target on the stock from $30.00 to $35.00. The stock had previously closed at $21.33, but opened at $21.86. Viking Therapeutics shares last traded at $21.48, with a volume of 510,823 shares traded. A […] ....
Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) CEO Brian Lian sold 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $21.45, for a total value of $750,750.00. Following the transaction, the chief executive officer now directly owns 2,242,963 shares in […] ....